07.07.26 -- Targeting Tau In Alzheimer's Disease With Voyager Therapeutics' Al Sandrock, M.D., Ph.D.

As CAR-T advances, shifting clinical progress and market dynamics are reshaping development strategies. Explore how evolving therapies and operational demands are redefining the next wave of innovation.

Learn how electroporation can be used to efficiently engineer T cells for CAR T cell manufacturing workflows with transposons while maintaining high viability and cell yield.

This panel session features the decade-long story of partnership that brought two life-changing gene therapies to market successfully in 2022.

It is crucial to start off your product development right. Find out how to best approach virus bank production. Review best practices, how to overcome common obstacles, and more.

Biotech visibility improves through real-time data and centralized platforms, enabling collaboration, faster decisions, reduced risk, and better partner alignment.

Discover how to deliver tailored, GMP-compliant automation solutions to your cell therapy manufacturing, which can accelerate innovation from process development to scalable production.

On this week's episode of the Business of Biotech, Al Sandrock, M.D., Ph.D., President and CEO at Voyager Therapeutics, talks about why tau is becoming a central target in Alzheimer’s drug development and how gene therapy delivery across the blood-brain barrier could change what treatment looks like at scale.